Decision Diagnostics Corp.
DECN · Other OTC · USD
0,0001USD
0,00 (0,00 %)Stand 10. Nov., 21:00
Kennzahlen
- Eröffnung
- 0,0001
- Vortag
- 0,0001
- Tagesspanne
- 0,0001 – 0,0001
- 52 Wochen
- 0,0001 – 0,0002
- Volumen
- 2 Mio.
- Ø Volumen
- 1,67 Mio.
- Börsenwert
- 35.787 $
- KGV
- -0,0
- Gewinn je Aktie (TTM)
- -0,03
- Dividendenrendite
- 0,0 %
- Beta
- -0,0
- Nächste Zahlen
- –
Finanzen
| USD | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
| Umsatz | 1,98 Mio. | 2,38 Mio. | 2,24 Mio. | 1,88 Mio. | 725.484 |
| Herstellungskosten | 1,48 Mio. | 1,53 Mio. | 1,93 Mio. | 1,95 Mio. | 476.718 |
| Bruttogewinn | 498.450 | 850.352 | 307.197 | −69.659 | 248.766 |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 2,31 Mio. | 1,73 Mio. | 2,16 Mio. | 2,29 Mio. | 2,87 Mio. |
| Operatives Ergebnis | −2,11 Mio. | −1,29 Mio. | −1,85 Mio. | −2,36 Mio. | −2,63 Mio. |
| EBITDA | −2,41 Mio. | −116.741 | −1,85 Mio. | −2,64 Mio. | 1,14 Mio. |
| Nettogewinn | −29,67 Mio. | −3,13 Mio. | −2,24 Mio. | −2,99 Mio. | −2,97 Mio. |
| Gewinn je Aktie (verwässert) | -0,11 | -0,02 | -0,02 | -0,03 | -0,04 |
Bewertung
Letzte 12 Monate
- KGV
- -0,0
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 0,1
- PEG
- -0,0
- Bruttomarge
- 25,2 %
- Operative Marge
- −106,7 %
- Nettomarge
- −1.499,1 %
- Verschuldungsgrad
- 6,0
- EV/EBITDA
- -1,0
- Eigenkapitalrendite
- −10.388,6 %
- Kapitalrendite (ROIC)
- −57,8 %
- Free-Cashflow-Rendite
- −3.925,9 %
| FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | |
|---|---|---|---|---|---|
| Bruttomarge | 25,2 % | 35,7 % | 13,7 % | −3,7 % | 34,3 % |
| Operative Marge | −106,7 % | −54,4 % | −82,9 % | −125,7 % | −361,9 % |
| Nettomarge | −1.499,1 % | −131,7 % | −100,2 % | −159,1 % | −409,0 % |
| KGV | -0,2 | -0,7 | -1,1 | -2,4 | -2,3 |
| Kurs-Umsatz-Verhältnis | 2,4 | 0,9 | 1,1 | 3,8 | 9,4 |
| Kurs-Buchwert-Verhältnis | 9,9 | 24,9 | 2,3 | 4,3 | 2,8 |
| Verschuldungsgrad | 6,0 | 31,9 | 1,4 | 1,2 | 0,9 |
| Liquidität 3. Grades | 0,3 | 0,3 | 0,6 | 0,8 | 1,1 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 7,2 Mio. | 4,86 Mio. | 3,67 Mio. | 8,01 Mio. | 7,77 Mio. |
| EV/EBITDA | -3,0 | -41,6 | -2,0 | -3,0 | 6,8 |
| Eigenkapitalrendite | −6.135,0 % | −3.576,3 % | −205,1 % | −182,4 % | −121,6 % |
| Kapitalrendite (ROIC) | −57,8 % | −37,4 % | −64,6 % | −60,4 % | −52,6 % |
| Free-Cashflow-Rendite | −29,3 % | −56,5 % | −56,5 % | −23,7 % | −41,7 % |
Wachstum
| FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | |
|---|---|---|---|---|---|
| Umsatz | −16,8 % | +6,4 % | +18,9 % | +159,2 % | +148,4 % |
| Bruttogewinn | −41,4 % | +176,8 % | +541,0 % | −128,0 % | +47,1 % |
| Operatives Ergebnis | −63,1 % | +30,2 % | +21,6 % | +9,9 % | −32,3 % |
| Nettogewinn | −847,2 % | −39,8 % | +25,1 % | −0,8 % | −34,5 % |
| Gewinn je Aktie | −428,8 % | −16,2 % | +43,5 % | +29,1 % | 0,0 % |
| Freier Cashflow | −14,1 % | +12,9 % | +15,6 % | +41,2 % | −88,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Sept. 2021 | Juni 2021 | Juni 2021 | Dez. 2020 | Sept. 2020 | Juni 2020 | März 2020 | Dez. 2019 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,00 | -0,00 | -0,00 | -0,03 | -0,02 | -0,06 | -0,00 | -0,01 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 518.511 | 552.385 | 537.799 | 1,98 Mio. | 520.698 | 362.864 | 573.793 | 2,38 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 28. Dez. 201111:10
- 1. Dez. 20111:14
- 3. Feb. 20061:80
- 17. Juli 200327:25
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
Führung
- Keith BermanChief Executive Officer, Chief Financial Officer, Secretary & Director
- CEO
- Keith Berman
- Mitarbeitende
- 6
- Hauptsitz
- Westlake Village, CA, US
- Sektor
- Healthcare
- Branche
- Medical - Pharmaceuticals
- Börsengang
- 8. Feb. 2002
- Website
- decisiondiagnostics.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.